GDOC
Goldman Sachs Future Health Care Equity ETF
GDOC is actively managed to provide exposure to equities of companies that are driving innovation in healthcare globally.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 21.4 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Inception date | Nov 09, 2021 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| ELI LILLY & CO | 13.3 % |
| JOHNSON & JOHNSON | 8.3 % |
| MERCK & CO. INC. | 6.6 % |
| GUARDANT HEALTH, INC. | 5.5 % |
| ASTRAZENECA PLC | 4.6 % |
| ARGENX SE ADR | 4.0 % |
| INTUITIVE SURGICAL INC | 3.8 % |
| DEXCOM INC | 3.5 % |
| CENCORA INC | 3.4 % |
| THERMO FISHER SCIENTIFIC INC | 3.3 % |
Constituent Breakdown
| Number of holdings | 42 |
| Herfindahl-Hirschman Index | 488 |
| Wgt avg mkt cap (mns) | $250,252 |
| Large cap (>$10bn) | 87.9% |
| Mid cap ($2-10bn) | 9.4% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 97.2% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 79.8 % |
 |
BRITAIN | 7.1 % |
 |
NETHERLANDS | 4.0 % |
 |
SWITZERLAND | 2.7 % |
 |
JAPAN | 2.5 % |
 |
IRELAND | 0.6 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 1.6% | 13.7% | 1.3% | 2.5% | -- | -- | -- | -2.0% |
| Dividend Yield | 0.0% | 0.4% | 0.2% | 0.3% | -- | -- | -- | 0.2% |
| Total Returns | 1.6% | 14.0% | 1.5% | 2.8% | -- | -- | -- | -1.9% | Ann. Volatility | 17.9% | 16.3% | 17.2% | 15.9% | -- | -- | -- | 18.8% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.59 | 20% |
| MSCI EAFE | 0.59 | 30% |
| MSCI Emg Mkts | 0.21 | 9% |
Liquidity Measures
| Avg. volume (000) | 4 |
| ADV traded (mns) | $0 |
| Turnover | 0.7% |
| Avg. Bid/Ask (% of price) | 0.48% |
Technical Indicators
| 30d moving avg. (EMA) | $35.18 |
| Relative strength (RSI) | 58 |
| MACD/Signal | 0.61/0.77 |
| Bollinger Bands (Upper/Lower) | $37.93/$33.60 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. GDOC |
Expenses vs. GDOC |
ALTAR Score™ vs. GDOC |
|---|---|---|---|---|
| HRTS | Tema Heart & Health ETF | 42.4% | 0 bp | +1.8% |
| IYH | iShares U.S. Healthcare ETF | 41.4% | -35 bp | +4.7% |
| FHLC | Fidelity MSCI Health Care Index ETF | 41.4% | -67 bp | +4.9% |
| VHT | Vanguard Health Care ETF | 40.8% | -66 bp | +4.0% |
| XLV | Health Care Select Sector SPDR | 40.6% | -67 bp | +5.5% |
| IXJ | iShares Global Healthcare ETF | 37.3% | -33 bp | +5.4% |
| MEDI | Harbor Health Care ETF | 35.3% | +5 bp | -2.3% |
| BMED | Future Health ETF | 32.2% | +10 bp | -0.3% |
| MEDX | Horizon Kinetics Medical ETF | 29.7% | +10 bp | +0.1% |
| IHE | iShares U.S. Pharmaceuticals ETF | 28.3% | -35 bp | +3.6% |
Risk and Returns: GDOC vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/22/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
1.4%
ALTAR SCORE™
12nd
PERCENTILE
AVOID
ETFRC RATING
There are 735 funds in the Global Equity category with an average
ALTAR Score™ of 4.4% and a standard deviation
of 2.6%. GDOC's ALTAR Score™ is approximately -1.2 standard
deviations above the category average. This places GDOC in the 12nd percentile
among funds in the category.
Sell-Side Consensus
$39.29
PRICE TARGET
+10.3%
UPSIDE
Bid/Ask Spreads
48 bp
AVG SPREAD
27 —
109 bp
RANGE